Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH -0.27%88 EV-to-EBIT is 34.12 as of Jul. 20, 2026, which is 6% above its 10-year median of 32.31. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.67 (Fairly Valued). The stock has 2 warning signs investors should review. Among 465 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 77.63% on this metric.
The historical rank and industry rank for Fisher & Paykel Healthcare's EV-to-EBIT or its related term are showing as below:
ASX:FPH'
s EV-to-EBIT Range Over the Past 10 Years
Min: 19.21 Med: 32.31 Max: 90.31
Current: 35.84
During the past 13 years, the highest EV-to-EBIT of Fisher & Paykel Healthcare was 90.31. The lowest was 19.21. And the median was 32.31.
ASX:FPH's EV-to-EBIT is ranked worse than 77.63% of 465
companies
in the Medical Devices & Instruments industry
Industry Median: 18.37
vs ASX:FPH: 35.84
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Fisher & Paykel Healthcare's Enterprise Value for the quarter that ended in Mar. 2026 was A$17,738 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$552 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare EV-to-EBIT Related Terms
Fisher & Paykel Healthcare EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's EV-to-EBIT falls into.
Fisher & Paykel Healthcare's current Enterprise Value is A$18,826 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$552 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a EV-to-EBIT of 34.12 as of Jul. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 32.31. Over the past decade, Fisher & Paykel Healthcare's EV-to-EBIT has ranged from 19.21 to 90.31. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #361 out of 465 companies in the Medical Devices & Instruments industry, placing it in the top 77.6%.
Is Fisher & Paykel Healthcare's EV-to-EBIT too high?
Fisher & Paykel Healthcare's current EV-to-EBIT of 34.12 is near median its 10-year median of 32.31. Over the past 10 years, this metric has ranged from a low of 19.21 to a high of 90.31. The Medical Devices & Instruments industry median EV-to-EBIT is 18.37. Fisher & Paykel Healthcare's value of 34.12 is 85.7% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #361 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #361 out of 465 companies for EV-to-EBIT. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median EV-to-EBIT is 18.37. Fisher & Paykel Healthcare's value of 34.12 is 85.7% above this benchmark. Historically, Fisher & Paykel Healthcare's own EV-to-EBIT has ranged from 19.21 to 90.31 over the past decade. While the company's 10-year median is 32.31 vs. the industry median of 18.37, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.37, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current EV-to-EBIT of 34.12 is 85.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current EV-to-EBIT is 34.12, which is near median its own 10-year median of 32.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.67, compared to a current price of A$33.22 — trading 9.4% below its estimated fair value. The current EV-to-EBIT is 34.12, which is near median its 10-year median of 32.31 and 85.7% above the Medical Devices & Instruments industry median of 18.37. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current EV-to-EBIT is 34.12 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$33.22 is trading 9.4% below its estimated GF Value™ of A$36.67.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
EV-to-EBIT: 34.12 (near median its 10-year median of 32.31)
GF Value™: A$36.67 vs. price of A$33.22 (9.4% below fair value)
Industry Position: 85.7% above the Medical Devices & Instruments median (#361 of 465)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
